Florida / New York
Ph: 561.316.3330
View the latest clinical trials, studies, data, and updates.
“This first study demonstrated quick application and easy activation of the NPsealTM,” stated Machiel van der Leest, CEO of Guard Medical. “This ease of use combined with its cost effectiveness makes prophylactic use of NPWT for closed surgical wounds possible.”
Conducted by a coalition of organizations, including the National Institute for Dementia Education, the CERTUS Institute, Vivid-Pix, Tellegacy, and achi, the group studied the healing power of photos and concluded that Photo Reminiscence Therapy (pRT) can minimize social isolation and improve medication compliance and general cognitive performance.
A total of 626 patients were randomized at 89 centers across the US, Canada, Europe, Australia, and Japan.
In tandem with the publication, the study results were presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons on January 30, 2022.
TRANSFORM II RCT, determined to explore and evaluate the treatment options in native coronary vessels, enrolled the index patient on the 16th December 2021 at Sandro Pertini Hospital, Rome, by the team of Dr. Alessandro Sciahbasi.
“This is not only a major milestone for FX, but for the next generation of stemless shoulder arthroplasty and the way we think about reverse total shoulder arthroplasty. As a small company, we are excited and humbled to lead the way and be the first to complete this historic study that may bring a novel device to the U.S. market which has already seen over 2000 implanted in Europe since 2015,” said Baptiste Martin, CEO of FX Shoulder USA.
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330